Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer
BACKGROUND: To determine the efficacy and safety profile of the combination of cisplatin and 5-fluorouracil modulated both by methotrexate and leucovorin in metastatic/recurrent squamous cell carcinoma of the head and neck.
METHODS: Twenty-eight patients were treated with cisplatin 40 mg/m2/day continuous infusion for 24 hours on day 1; high-dose 5-fluorouracil 2,000 mg/m2/day and leucovorin 100 mg/m2/day continuous infusion for 48 hours on days 1 and 2; methotrexate 40 mg/m2/day as a bolus infusion 4 hours before 5-fluorouracil and leucovorin on day 1. The treatment was repeated every 2 weeks in a cycle.
RESULTS: The overall response rate was 25%, and 14% of the patients achieved stable disease status. Subgroup analysis demonstrated significantly improved overall survival in the disease-control group (12.0 months vs. 5.3 months, p<0.001). Only 3 (10.7%) patients developed grade 3-4 neutropenia, and none developed grade 3-4 non-hematologic toxicity.
CONCLUSION: This multiagent-containing regimen has an excellent safety profile and improved survival in disease-control group of patients with metastatic/recurrent squamous cell carcinoma of the head and neck.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Journal of the Chinese Medical Association : JCMA - 71(2008), 7 vom: 05. Juli, Seite 336-41 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chang, Peter Mu-Hsin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
12001-76-2 |
|---|
| Anmerkungen: |
Date Completed 23.10.2008 Date Revised 17.01.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1726-4901(08)70135-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM181152231 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM181152231 | ||
| 003 | DE-627 | ||
| 005 | 20231223160733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1726-4901(08)70135-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0604.xml |
| 035 | |a (DE-627)NLM181152231 | ||
| 035 | |a (NLM)18653395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chang, Peter Mu-Hsin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2008 | ||
| 500 | |a Date Revised 17.01.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: To determine the efficacy and safety profile of the combination of cisplatin and 5-fluorouracil modulated both by methotrexate and leucovorin in metastatic/recurrent squamous cell carcinoma of the head and neck | ||
| 520 | |a METHODS: Twenty-eight patients were treated with cisplatin 40 mg/m2/day continuous infusion for 24 hours on day 1; high-dose 5-fluorouracil 2,000 mg/m2/day and leucovorin 100 mg/m2/day continuous infusion for 48 hours on days 1 and 2; methotrexate 40 mg/m2/day as a bolus infusion 4 hours before 5-fluorouracil and leucovorin on day 1. The treatment was repeated every 2 weeks in a cycle | ||
| 520 | |a RESULTS: The overall response rate was 25%, and 14% of the patients achieved stable disease status. Subgroup analysis demonstrated significantly improved overall survival in the disease-control group (12.0 months vs. 5.3 months, p<0.001). Only 3 (10.7%) patients developed grade 3-4 neutropenia, and none developed grade 3-4 non-hematologic toxicity | ||
| 520 | |a CONCLUSION: This multiagent-containing regimen has an excellent safety profile and improved survival in disease-control group of patients with metastatic/recurrent squamous cell carcinoma of the head and neck | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 650 | 7 | |a Vitamin B Complex |2 NLM | |
| 650 | 7 | |a 12001-76-2 |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Teng, Hao-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Po-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Shyue-Yih |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Pen-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Tung-Lung |e verfasserin |4 aut | |
| 700 | 1 | |a Tai, Shyh-Kuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yi-Fen |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jui-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Muh-Hwa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Chinese Medical Association : JCMA |d 2003 |g 71(2008), 7 vom: 05. Juli, Seite 336-41 |w (DE-627)NLM124866131 |x 1728-7731 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2008 |g number:7 |g day:05 |g month:07 |g pages:336-41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1726-4901(08)70135-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2008 |e 7 |b 05 |c 07 |h 336-41 | ||